Andina Capital Management LLC Buys New Position in Zoetis Inc. $ZTS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Andina Capital Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,487 shares of the company's stock, valued at approximately $574,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZTS. Texas Capital Bank Wealth Management Services Inc grew its stake in shares of Zoetis by 24.2% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 51,783 shares of the company's stock valued at $8,526,000 after acquiring an additional 10,091 shares in the last quarter. CWS Financial Advisors LLC boosted its holdings in Zoetis by 27.0% in the 1st quarter. CWS Financial Advisors LLC now owns 3,746 shares of the company's stock valued at $617,000 after purchasing an additional 797 shares during the period. Colonial Trust Advisors grew its position in shares of Zoetis by 3.9% during the 1st quarter. Colonial Trust Advisors now owns 33,518 shares of the company's stock worth $5,519,000 after purchasing an additional 1,251 shares in the last quarter. Bank OZK increased its holdings in shares of Zoetis by 702.8% during the first quarter. Bank OZK now owns 13,567 shares of the company's stock worth $2,234,000 after purchasing an additional 11,877 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Zoetis by 73.6% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 526,492 shares of the company's stock valued at $86,682,000 after buying an additional 223,295 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ZTS shares. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Price Performance

ZTS stock traded down $1.2650 during trading on Thursday, reaching $155.4950. 2,411,616 shares of the company were exchanged, compared to its average volume of 3,540,633. The company has a 50-day moving average of $154.00 and a two-hundred day moving average of $158.75. The company has a market capitalization of $68.91 billion, a price-to-earnings ratio of 26.76, a P/E/G ratio of 2.52 and a beta of 0.88. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the prior year, the company earned $1.56 EPS. Zoetis's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.